Immupharma PLC Share Price Volatility (5515W)
December 11 2019 - 7:49AM
UK Regulatory
TIDMIMM
RNS Number : 5515W
Immupharma PLC
11 December 2019
11 December 2019
ImmuPharma PLC
("ImmuPharma" or the "Company")
SHARE PRICE VOLATILITY
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and
development company, announces that following the recently
announced licensing and development agreement with Avion, the US
speciality pharmaceutical company, in which Avion will fund an
international Phase III trial for our lead programme, Lupuzor(TM),
we note the volatility in the Company's share price and speculation
concerning a possible fundraising. The Board can confirm that the
Company is adequately funded and has no intention of raising
funds.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact:
ImmuPharma PLC (www.immupharma.com)
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 368 8974
Vassil Kirtchev
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (AIM: IMM) is a specialty biopharmaceutical
company that discovers and develops peptide-based therapeutics. The
Company's portfolio includes novel peptide therapeutics for
autoimmune diseases, metabolic diseases and cancer. The lead
program, Lupuzor(TM) , is a first-in class autophagy
immunomodulator which is in Phase III for the treatment of lupus
and preclinical analysis suggest therapeutic activity for many
other autoimmune diseases that share the same autophagy mechanism
of action. For additional information about ImmuPharma please visit
www.immupharma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCBDBDDLSBBGCB
(END) Dow Jones Newswires
December 11, 2019 07:49 ET (12:49 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024